Sawyer & Company Inc Decreases Stock Holdings in Cencora, Inc. (NYSE:COR)

Sawyer & Company Inc lowered its stake in shares of Cencora, Inc. (NYSE:COR) by 9.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,115 shares of the company’s stock after selling 1,242 shares during the quarter. Sawyer & Company Inc’s holdings in Cencora were worth $2,727,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of COR. Fisher Asset Management LLC acquired a new position in Cencora in the 4th quarter worth approximately $244,000. Trust Co. of Vermont acquired a new stake in shares of Cencora during the 4th quarter worth approximately $62,000. Wahed Invest LLC acquired a new stake in shares of Cencora during the 4th quarter worth approximately $567,000. Vanguard Group Inc. acquired a new stake in shares of Cencora during the 4th quarter worth approximately $4,212,508,000. Finally, M3 Advisory Group LLC acquired a new stake in shares of Cencora during the 4th quarter worth approximately $243,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Activity at Cencora

In other news, CEO Steven H. Collis sold 10,755 shares of the stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total value of $2,388,900.60. Following the completion of the sale, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at approximately $63,323,746.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Silvana Battaglia sold 1,473 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the sale, the executive vice president now owns 10,948 shares in the company, valued at $2,656,970.12. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Steven H. Collis sold 10,755 shares of the company’s stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total value of $2,388,900.60. Following the sale, the chief executive officer now owns 285,088 shares of the company’s stock, valued at $63,323,746.56. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,450,399 shares of company stock valued at $1,070,392,799 over the last three months. 15.80% of the stock is owned by corporate insiders.

Cencora Stock Up 0.2 %

Shares of Cencora stock traded up $0.36 on Friday, reaching $222.56. 938,026 shares of the company were exchanged, compared to its average volume of 1,413,334. The stock’s 50 day moving average price is $232.97 and its 200-day moving average price is $231.40. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55. The company has a market cap of $44.39 billion, a P/E ratio of 24.35, a price-to-earnings-growth ratio of 1.40 and a beta of 0.44. Cencora, Inc. has a 1-year low of $182.75 and a 1-year high of $247.66.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. The firm had revenue of $74.20 billion during the quarter, compared to the consensus estimate of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The firm’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same period in the prior year, the company posted $2.92 earnings per share. As a group, equities analysts forecast that Cencora, Inc. will post 13.63 EPS for the current year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were issued a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date of this dividend was Friday, August 9th. Cencora’s dividend payout ratio (DPR) is 22.32%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on COR shares. Leerink Partners dropped their price objective on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. Robert W. Baird cut their target price on Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a research note on Friday, September 6th. Wells Fargo & Company boosted their price objective on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. Bank of America reiterated a “neutral” rating and set a $245.00 price target (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Finally, Evercore ISI cut their price target on shares of Cencora from $270.00 to $250.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Cencora has an average rating of “Moderate Buy” and a consensus target price of $259.44.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.